© 2018 American Society for Microbiology. All Rights Reserved. The aim of this study was to investigate the efficacy of ceftolozane-tazobactam in combination with meropenem against an extensively drug-resistant (XDR) Pseudomonas aeruginosa high-risk clone, sequence type 175, isolated in a Spanish university hospital. A 14-day hollow-fiber infection model was used to simulate clinical exposure of the two drug regimens alone and in combination, and serial samples were collected to determine drug concentrations and CFU counts. The untreated control failed, as did each study regimen when administered alone. However, when ceftolozane-tazobactam was administered in combination with meropenem, there was a >4-log10 CFU/ml bacterial density reduction and suppression of resistance for the duration of the study. These data suggest that ceftolozane-tazobactam plus meropenem may be a useful combination for treating XDR P. aeruginosa.
|Journal||Antimicrobial Agents and Chemotherapy|
|Publication status||Published - 1 May 2018|
- Multidrug resistance
- Pseudomonas aeruginosa
Montero, M., VanScoy, B. D., López-Causapé, C., Conde, H., Adams, J., Segura, C., Zamorano, L., Oliver, A., Horcajada, J. P., & Ambrose, P. G. (2018). Evaluation of ceftolozane-tazobactam in combination with meropenem against pseudomonas aeruginosa sequence type 175 in a hollow-fiber infection model. Antimicrobial Agents and Chemotherapy, 62(5), [e00026]. https://doi.org/10.1128/AAC.00026-18